- Featured Product
- KD/KO Validated
TMEM106B (150-274aa) Polyclonal antibody
TMEM106B (150-274aa) Polyclonal Antibody for WB, IHC, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse
Applications
WB, IHC, IF, ELISA
Conjugate
Unconjugated
Cat no : 20995-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive WB detected in | A549 cells, HeLa cells, HepG2 cells |
Positive IHC detected in | rat brain tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:500-1:2000 |
Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Published Applications
WB | See 6 publications below |
IF | See 3 publications below |
Product Information
20995-1-AP targets TMEM106B (150-274aa) in WB, IHC, IF, ELISA applications and shows reactivity with human, mouse samples.
Tested Reactivity | human, mouse |
Cited Reactivity | human, mouse |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | TMEM106B (150-274aa) fusion protein Ag14264 相同性解析による交差性が予測される生物種 |
Full Name | transmembrane protein 106B |
Calculated molecular weight | 31 kDa |
Observed molecular weight | 31-35 kDa, 40-55 kDa |
GenBank accession number | BC033901 |
Gene symbol | TMEM106B |
Gene ID (NCBI) | 54664 |
RRID | AB_10694293 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
TMEM106B is a genetic risk factor for frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP). Amyotrophic lateral sclerosis (ALS), like FTLD-TDP, is characterized by pathological TDP-43 inclusions. TMEM106B expression in the brain may be linked to mechanisms of disease in FTLD-TDP and risk alleles confer genetic susceptibility by increasing gene expression. TMEM106B can be showed as 31-55 kDa and 70-90 kDa (Glycosylated or Dimer) form in western blot test. (PMID: 27543298, 22895706, PMID: 23136129).
Protocols
Product Specific Protocols | |
---|---|
WB protocol for TMEM106B (150-274aa) antibody 20995-1-AP | Download protocol |
IHC protocol for TMEM106B (150-274aa) antibody 20995-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
J Neuroinflammation Progranulin haploinsufficiency mediates cytoplasmic TDP-43 aggregation with lysosomal abnormalities in human microglia | ||
J Neurosci TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. | ||
Mol Brain TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD-3-linked CHMP2B, a complex of ESCRT-III. | ||
PLoS One Construction of ceRNA network to identify the lncRNA and mRNA related to non-small cell lung cancer. |
Reviews
The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.
FH Carolyn (Verified Customer) (02-18-2022) | good signal, low background
|